


Claim amendments:

1. – 43. (cancelled)

44. (currently amended) A compound of the formula:



where:

each of W, X and Y is independently CR⁶R⁷, N-R⁷, O, or S, provided that at least one of W, X, and Y contains a non-carbon ring atom, and at least one of W, X, and Y contains a carbon ring atom;

Z is N or C-R⁸;

each of R¹, R², R⁶, and R⁸ is independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted

heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR⁹, -SR⁹,

-NR⁹R¹⁰, -NR⁹(carboxy(lower alkyl)), -C(=O)R⁹, -C(=O)OR⁹, -C(=O)NR⁹R¹⁰,

-OC(=O)R⁹, -SO₂R⁹, -OSO₂R⁹, -SO₂NR⁹R¹⁰,

-NR⁹SO₂R¹⁰, or -NR⁹C(=O)R¹⁰, where R⁹ and R¹⁰ are independently hydrogen,

optionally substituted lower alkyl, lower alkyl-N(C₁₋₂ alkyl)₂, lower alkyl(optionally

substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl,

cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower

alkyl), optionally substituted aryl, optionally substituted heteroaryl, or heteroaryl(lower

alkyl), or R⁹ and R¹⁰ together are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH,

N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁₋₂ alkyl) group;

R³ and R⁴ are independently hydrogen or lower alkyl or together are -(CH₂)₄₋₆;

each R⁷ is independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally

substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), $-C(=O)R^9$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2R^9$, or $-SO_2NR^9R^{10}$, where R^9 and R^{10} are independently hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2} \text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, or heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)), or N-(optionally substituted C_{1-2} alkyl) group;

R^{13} is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), $-CF_3$, halo(lower alkyl), halogen, nitro, $-CN$, $-OR^{15}$, $-SR^{15}$, $-NR^{15}R^{16}$, $-C(=O)R^{15}$, $-C(=O)OR^{15}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)R^{15}$, $-SO_2R^{15}$, $-SO_2NR^{15}R^{16}$, $-NR^{15}SO_2R^{16}$, or $-NR^{15}C(=O)R^{16}$, where R^{15} and R^{16} are independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, $-CF_3$, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heteroaryl(lower alkyl), or together are $-(CH_2)_{4-6}$ optionally interrupted by one O, S, NH or N- $(C_{1-2} \text{ alkyl})$ group; each R^{14} is independently optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, $-CF_3$, $-OR^{17}$, $-NR^{17}R^{18}$, $-C(=O)R^{17}$, $-C(=O)OR^{17}$, $-O(CH_2)_mC(=O)OR^{17}$, where m is an integer of 1 to 4, or $-C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are independently, hydrogen, lower alkyl, alkenyl, alkynyl, $-CF_3$, optionally substituted heterocycloalkyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl) or, together, are $-(CH_2)_{4-6}$, optionally interrupted by one O, S, NH or N- $(C_{1-2} \text{ alkyl})$ group; and

n is an integer of 0 to 4;

or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

45. (previously presented) The compound of claim 44, where W and Y are O, X is CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is C-H.

46. (previously presented) The compound of claim 44, where W and X are each CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, Y is O, and Z is C-H.

47. (previously presented) The compound of claim 44, where W is O, X and Y are each CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is C-H.

48. (previously presented) The compound of claim 44, where W and X are each CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is N.

49. (previously presented) The compound of claim 44, where W is CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, X is O, and Z is N.

50. (previously presented) The compound of claim 44, where W is O, X is CR^6R^7 , where R^6 and R^7 are independently hydrogen, lower alkyl, or optionally substituted aryl, and Z is N.

51. (previously presented) The compound of claim 44, where R^1 is hydrogen, optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, $-\text{OR}^9$, $-\text{NR}^9[\text{carboxy(lower alkyl)}]$, $-\text{C}(=\text{O})\text{OR}^9$, $-\text{C}(=\text{O})\text{NR}^9\text{R}^{10}$, $-\text{SO}_2\text{NR}^9\text{R}^{10}$, or $-\text{NR}^9\text{C}(=\text{O})\text{R}^{10}$, where R^9 and R^{10} are independently hydrogen, optionally substituted lower alkyl, lower alkyl- $\text{N}(\text{C}_{1-2} \text{ alkyl})_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10}

together are $-(CH_2)_{4-6}$ - optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

52. (previously presented) The compound of claim 44, where R^2 is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)OR^9$, or $-C(=O)NR^9R^{10}$, where R^9 and R^{10} are independently hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2}$ alkyl) $_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}$ - optionally interrupted by one O, S, NH, N-(aryl), N-[aryl(lower alkyl)], N-(carboxy(lower alkyl)) or N-(optionally substituted C_{1-2} alkyl) group.

53. (previously presented) The compound of claim 44 where R^3 and R^4 are independently hydrogen or lower alkyl.

54. (previously presented) The compound of claim 44, where R^6 and R^7 are independently hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), $-C(=O)R^9$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2R^9$, or $-SO_2NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl- $N(C_{1-2}$ alkyl) $_2$, alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).

55. (previously presented) The compound of claim 44, where R^8 is hydrogen, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)R^9$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-OC(=O)R^9$, $-SO_2R^9$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{10}$ or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen,

optionally substituted lower alkyl, lower alkyl-N(C₁₋₂ alkyl)₂, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R⁹ and R¹⁰ together are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁₋₂ alkyl) group.

56. (previously presented) The compound of claim 44, where R¹ and R² are independently hydrogen, lower alkyl, halogen, optionally lower alkyl substituted heterocycloalkyl, -OR⁹, -SR⁹, or -NR⁹R¹⁰, where R⁹ and R¹⁰ are hydrogen, lower alkyl or optionally substituted aryl.

57. (previously presented) The compound of claim 44, where R¹, R², and R⁸ are independently optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, -OR⁹, -NR⁹[carboxy(lower alkyl)], -C(=O)OR⁹, -C(=O)NR⁹R¹⁰, -SO₂NR⁹R¹⁰, or -NR⁹C(=O)R¹⁰, where R⁹ and R¹⁰ are independently, hydrogen, lower alkyl, or R⁹ and R¹⁰ together are -(CH₂)₄₋₆- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-(carboxy(lower alkyl)) or N-(optionally substituted C₁₋₂ alkyl) group.

58. (previously presented) The compound of claim 44, where R¹, R³, and R⁴ are hydrogen.

59. (previously presented) The compound of claim 44, where R¹³ is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), -CF₃, halogen, nitro, -CN, -OR¹⁵, -SR¹⁵, -NR¹⁵R¹⁶, -C(=O)R¹⁵, -C(=O)OR¹⁵, -C(=O)NR¹⁵R¹⁶, or -NR¹⁵C(=O)R¹⁶, where R¹⁵ and R¹⁶ are independently hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, or halo(lower alkyl).

60. (previously presented) The compound of claim 44, where R¹³ is alkynyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, -CF₃, -CN, -OR¹⁵,

-C(=O)R¹⁵, -C(=O)OR¹⁵, or -C(=O)NR¹⁵R¹⁶, where R¹⁵ and R¹⁶ are independently, hydrogen, lower alkyl, halo(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, heteroaryl(lower alkyl) or R¹⁵ and R¹⁶ together are -(CH₂)₄₋₆-, optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group.

61. (previously presented) The compound of claim 44, where each R¹⁴ is independently optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, -CF₃, -OR¹⁷, -NR¹⁷R¹⁸, -C(=O)R¹⁷, -C(=O)OR¹⁷, -O(CH₂)_mC(=O)OR¹⁷, where m is an integer of 1 to 4, or -C(=O)NR¹⁷R¹⁸, where R¹⁷ and R¹⁸ are, independently, hydrogen, lower alkyl, alkenyl, or optionally substituted aryl.

62. (previously presented) The compound of claim 44, where each R¹⁴ is independently halogen, -CF₃, -OR¹⁷, -C(=O)OR¹⁷, -O(CH₂)_mC(=O)OR¹⁷, where m is an integer of 1 to 4, or -C(=O)NR¹⁷R¹⁸, where R¹⁷ and R¹⁸ are independently, hydrogen, lower alkyl, optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl), or R¹⁷ and R¹⁸ together are -(CH₂)₄₋₆-, optionally interrupted by one O, S, NH or N-(C₁₋₂ alkyl) group.

63. (previously presented) The compound of claim 44 where R¹³ is not hydrogen and n is 1 or 2.

64. (previously presented) The compound of claim 63 where n is 1.

65. (previously presented) The compound of claim 44 that is selected from:

2H-benzo[d]1,3-dioxolan-5-yl-N-{(3-chloro-4-hydroxyphenyl)amino}carbonyl}-carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{(3,4-dichlorophenyl)amino}carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-([2,6-bis(methylethyl)phenyl]amino}carbonyl)-carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{(4-hydroxyphenyl)amino}carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-{(3-chloro-4-methoxyphenyl)amino}carbonyl}-

carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-[[[(3-chlorophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-[(phenylamino)carbonyl]carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(5-chloro-2-hydroxyphenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(3-fluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(2,6-difluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(2,3-difluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(4-fluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(4-chlorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(3,4-difluorophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([[(4-(trifluoromethyl)phenyl]amino}carbonyl)-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([[(3-(trifluoromethyl)phenyl]amino}carbonyl)-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(4-nitrophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([[(4-nitro-3-(trifluoromethyl)phenyl]amino}-
carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([[(4-chloro-3-(trifluoromethyl)phenyl]amino}-
carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(4-bromophenyl)amino]carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-[[[(3-bromophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-[[[(3-cyanophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-[[[(2,4-dichlorophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-[[[(4-methoxyphenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-[[[(4-iodophenyl)amino]carbonyl}carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-[[[(3-iodophenyl)amino]carbonyl}carboxamide;

4-[[[(2H-benzo[d]1,3-dioxolan-5-ylcarbonylamino)carbonyl]amino}benzamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-([[(3-fluoro-4-(trifluoromethyl)phenyl]amino}carbonyl)-
carboxamide;

2H-benzo[d]1,3-dioxolan-5-yl-N-([4-fluoro-3-(trifluoromethyl)phenyl]amino)carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(4-phenylphenyl)amino]carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([3-(trifluoromethoxy)phenyl]amino)carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([3-(trifluoromethylthio)phenyl]amino)carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([3,5-bis(trifluoromethyl)phenyl]amino)carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([3-(methylethyl)phenyl]amino)carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3-ethylphenyl)amino]carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3-ethoxyphenyl)amino]carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([3-(methylethoxy)phenyl]amino)carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([3-(tert-butyl)phenyl]amino)carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3-phenylphenyl)amino]carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3-chloro-4-methylphenyl)amino]carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3-iodo-4-methylphenyl)amino]carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([4-methyl-3-(trifluoromethyl)phenyl]amino)carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3-phenoxyphenyl)amino]carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3-nitrophenyl)amino]carbonyl)carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3,5-dichlorophenyl)amino]carbonyl)-carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-([(3-acetylphenyl)amino]carbonyl)carboxamide;

methyl 3-([(2H-benzo[3,4-d]1,3-dioxolen-5-ylcarbonylamino)carbonyl]amino)benzoate;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(1H-1,2,3,4-tetraazol-5-yl)phenyl)amino]-
carbonyl}carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-ethynylphenyl)amino]carbonyl} carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-chloro-2-methylphenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(5-chloro-2-methylphenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-chloro-2,6-diethylphenyl)amino]carbonyl} -
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(5-iodo-2-methylphenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(2-pyridyl)phenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(1,3-thiazol-2-yl)phenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(3-thienyl)phenyl)amino]carbonyl}-
carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(2-furyl)phenyl)amino]carbonyl} carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N- {[(3-(2-thienyl)phenyl)amino]carbonyl}-
carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- {[(3-icyanophenyl)amino]carbonyl}-
carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- {[(3-iodophenyl)amino]carbonyl}-
carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- ({ [3-(trifluoromethyl)phenyl]amino } -
carbonyl)carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- ({ [3-(methylethoxy)phenyl]amino } -
carbonyl)carboxamide;

(6-chloro(2H-benzo[3,4-d]1,3-dioxolen-5-yl))-N- ({ [4-fluoro-3-(trifluoromethyl)phenyl]-
amino } carbonyl) carboxamide;

2H-benzo[3,4-d]1,3-dioxolen-5-yl-N-{{[(3-chlorophenyl)methylamino]carbonyl}-N-methylcarboxamide;
2H-benzo[d]1,3-dioxolan-5-yl-N-{{[(3-chlorophenyl)amino]carbonyl}-N-methylcarboxamide;
N-{{[(3,4-dichlorophenyl)amino]carbonyl}-2,3-dihydrobenzo[b]furan-5-ylcarboxamide;
N-{{[(3-chlorophenyl)amino]carbonyl}-2,3-dihydrobenzo[b]furan-5-ylcarboxamide;
2,3-dihydrobenzo[b]furan-5-yl-N-({[4-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;
2,3-dihydrobenzo[b]furan-5-yl-N-{{[(4-fluorophenyl)amino]carbonyl}carboxamide; and
2,3-dihydrobenzo[b]furan-5-yl-N-{{[(4-methoxyphenyl)amino]carbonyl}carboxamide;
and the pharmaceutically acceptable salts thereof, as single stereoisomers or mixtures of stereoisomers.

66. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 44 and a pharmaceutically acceptable excipient.

67. (previously presented) The pharmaceutical composition of claim 66, further comprising an anti-inflammatory drug, cytokine, or immunomodulator.

68. (previously presented) A method of treating an allergic, inflammatory, or autoimmune disorder or disease, comprising administering a therapeutically effective amount of a compound of claim 44 to a mammal in need of such treatment.

69. (previously presented) The method of claim 68 where the compound is administered in combination with an anti-inflammatory drug, cytokine, or immunomodulator.

70. (previously presented) The method of claim 68 where the allergic, inflammatory, or autoimmune disorder or disease is selected from the group consisting of asthma, atherosclerosis, glomerulonephritis, pancreatitis, restenosis, rheumatoid arthritis, diabetic nephropathy, pulmonary fibrosis, inflammatory bowel disease, Crohn's disease, and transplant rejection.

71. (previously presented) The method of claim 68 where the allergic, inflammatory, or autoimmune disorder or disease is associated with lymphocyte and/or monocyte accumulation.

72. (previously presented) A method of inhibiting leukocyte migration, comprising administering a therapeutically effective amount of a compound of claim 44 to a mammal in need of such treatment.